RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA

Clinical trials for RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA trials appear

Sign up with your email to follow new studies for RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Targeted drug tested for Tough-to-Treat female cancers

Disease control Terminated

This study aimed to test if a drug called sacituzumab govitecan could help control recurrent ovarian, endometrial, or cervical cancers that had returned after at least two prior treatments. The drug was given by IV infusion to see if it could shrink tumors. The trial was terminat…

Matched conditions: RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 02, 2026 15:27 UTC

RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA

Get alerted when new RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CARCINOMA trials appear

Targeted drug tested for Tough-to-Treat female cancers